| 1 |
35452936 | Synthesis and evaluation of novel HER-2 inhibitors to exert anti-breast cancer ability through epithelial-mesenchymal transition (EMT) pathway. | 2022 Jul 5 |
1 |
| 2 |
33245718 | Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism. | 2020 Nov 17 |
2 |
| 3 |
30639343 | Dysfunctional ErbB2, an EGF receptor family member, hinders repair of airway epithelial cells from asthmatic patients. | 2019 Jun |
1 |
| 4 |
31287994 | Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. | 2019 Jul 8 |
1 |
| 5 |
29374185 | Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death. | 2018 Jan 26 |
2 |
| 6 |
30139932 | Effectiveness of EGFR/HER2-targeted drugs is influenced by the downstream interaction shifts of PTPIP51 in HER2-amplified breast cancer cells. | 2018 Aug 24 |
2 |
| 7 |
25407459 | Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. | 2016 Jan |
1 |
| 8 |
27074819 | The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARĪ±/STAT1 axis. | 2016 Apr 14 |
2 |
| 9 |
26018524 | Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. | 2015 |
1 |
| 10 |
16771730 | Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. | 2006 May |
3 |
| 11 |
15138566 | Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. | 2004 Jun |
4 |